552 related articles for article (PubMed ID: 21212415)
1. Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies.
Hu-Lowe DD; Chen E; Zhang L; Watson KD; Mancuso P; Lappin P; Wickman G; Chen JH; Wang J; Jiang X; Amundson K; Simon R; Erbersdobler A; Bergqvist S; Feng Z; Swanson TA; Simmons BH; Lippincott J; Casperson GF; Levin WJ; Stampino CG; Shalinsky DR; Ferrara KW; Fiedler W; Bertolini F
Cancer Res; 2011 Feb; 71(4):1362-73. PubMed ID: 21212415
[TBL] [Abstract][Full Text] [Related]
2. Activin receptor-like kinase 1 as a target for anti-angiogenesis therapy.
Hawinkels LJ; Garcia de Vinuesa A; Ten Dijke P
Expert Opin Investig Drugs; 2013 Nov; 22(11):1371-83. PubMed ID: 24053899
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic therapies targeting the vascular endothelia growth factor signaling system.
Tie J; Desai J
Crit Rev Oncog; 2012; 17(1):51-67. PubMed ID: 22471664
[TBL] [Abstract][Full Text] [Related]
4. Targeting tumour vasculature by inhibiting activin receptor-like kinase (ALK)1 function.
de Vinuesa AG; Bocci M; Pietras K; Ten Dijke P
Biochem Soc Trans; 2016 Aug; 44(4):1142-9. PubMed ID: 27528762
[TBL] [Abstract][Full Text] [Related]
5. Dual targeting of vascular endothelial growth factor and bone morphogenetic protein-9/10 impairs tumor growth through inhibition of angiogenesis.
Akatsu Y; Yoshimatsu Y; Tomizawa T; Takahashi K; Katsura A; Miyazono K; Watabe T
Cancer Sci; 2017 Jan; 108(1):151-155. PubMed ID: 28133920
[TBL] [Abstract][Full Text] [Related]
6. BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis.
Scharpfenecker M; van Dinther M; Liu Z; van Bezooijen RL; Zhao Q; Pukac L; Löwik CW; ten Dijke P
J Cell Sci; 2007 Mar; 120(Pt 6):964-72. PubMed ID: 17311849
[TBL] [Abstract][Full Text] [Related]
7. Molecular pathways: can activin-like kinase pathway inhibition enhance the limited efficacy of VEGF inhibitors?
Bhatt RS; Atkins MB
Clin Cancer Res; 2014 Jun; 20(11):2838-45. PubMed ID: 24714770
[TBL] [Abstract][Full Text] [Related]
8. Activin Receptor-like Kinase 1 Ligand Trap Reduces Microvascular Density and Improves Chemotherapy Efficiency to Various Solid Tumors.
Hawinkels LJ; de Vinuesa AG; Paauwe M; Kruithof-de Julio M; Wiercinska E; Pardali E; Mezzanotte L; Keereweer S; Braumuller TM; Heijkants RC; Jonkers J; Löwik CW; Goumans MJ; ten Hagen TL; ten Dijke P
Clin Cancer Res; 2016 Jan; 22(1):96-106. PubMed ID: 26373572
[TBL] [Abstract][Full Text] [Related]
9. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
10. Complementary actions of dopamine D2 receptor agonist and anti-vegf therapy on tumoral vessel normalization in a transgenic mouse model.
Chauvet N; Romanò N; Lafont C; Guillou A; Galibert E; Bonnefont X; Le Tissier P; Fedele M; Fusco A; Mollard P; Coutry N
Int J Cancer; 2017 May; 140(9):2150-2161. PubMed ID: 28152577
[TBL] [Abstract][Full Text] [Related]
11. Anti-Angiogenics: Current Situation and Future Perspectives.
Zirlik K; Duyster J
Oncol Res Treat; 2018; 41(4):166-171. PubMed ID: 29562226
[TBL] [Abstract][Full Text] [Related]
12. Metformin inhibits ALK1-mediated angiogenesis via activation of AMPK.
Ying Y; Ueta T; Jiang S; Lin H; Wang Y; Vavvas D; Wen R; Chen YG; Luo Z
Oncotarget; 2017 May; 8(20):32794-32806. PubMed ID: 28427181
[TBL] [Abstract][Full Text] [Related]
13. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
14. Anti-human activin receptor-like kinase 1 (ALK1) antibody attenuates bone morphogenetic protein 9 (BMP9)-induced ALK1 signaling and interferes with endothelial cell sprouting.
van Meeteren LA; Thorikay M; Bergqvist S; Pardali E; Stampino CG; Hu-Lowe D; Goumans MJ; ten Dijke P
J Biol Chem; 2012 May; 287(22):18551-61. PubMed ID: 22493445
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma.
Wang X; Solban N; Khanna P; Callea M; Song J; Alsop DC; Pearsall RS; Atkins MB; Mier JW; Signoretti S; Alimzhanov M; Kumar R; Bhasin MK; Bhatt RS
Oncotarget; 2016 Jul; 7(27):41857-41869. PubMed ID: 27248821
[TBL] [Abstract][Full Text] [Related]
16. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
[TBL] [Abstract][Full Text] [Related]
17. Clinically relevant concentrations of lidocaine inhibit tumor angiogenesis through suppressing VEGF/VEGFR2 signaling.
Gao J; Hu H; Wang X
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1007-1015. PubMed ID: 30887179
[TBL] [Abstract][Full Text] [Related]
18. P7170: A Novel Molecule with Unique Profile of mTORC1/C2 and Activin Receptor-like Kinase 1 Inhibition Leading to Antitumor and Antiangiogenic Activity.
Jalota-Badhwar A; Bhatia DR; Boreddy S; Joshi A; Venkatraman M; Desai N; Chaudhari S; Bose J; Kolla LS; Deore V; Yewalkar N; Kumar S; Sharma R; Damre A; More A; Sharma S; Agarwal VR
Mol Cancer Ther; 2015 May; 14(5):1095-106. PubMed ID: 25700704
[TBL] [Abstract][Full Text] [Related]
19. Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model.
Iwai T; Sugimoto M; Harada S; Yorozu K; Kurasawa M; Yamamoto K
Oncol Rep; 2016 Aug; 36(2):626-32. PubMed ID: 27350037
[TBL] [Abstract][Full Text] [Related]
20. Morelloflavone, a biflavonoid, inhibits tumor angiogenesis by targeting rho GTPases and extracellular signal-regulated kinase signaling pathways.
Pang X; Yi T; Yi Z; Cho SG; Qu W; Pinkaew D; Fujise K; Liu M
Cancer Res; 2009 Jan; 69(2):518-25. PubMed ID: 19147565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
